MGNX — MACROGENICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1125345 ·
Last close
$2.05
Market Cap
$131.01M
52W High
$5.08
52W Low
$1.32
ADV30
919,400
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 18,667,000 | — | -20,303,000 | -20,076,000 | 318,685,000 | 49,029,000 | 293,534,000 |
| Jun 2026 | 32,832,000 | — | -13,852,000 | 19,515,000 | 345,409,000 | 113,907,000 | 302,536,000 |
| Mar 2026 | 20,775,000 | 11,245,000 | -33,439,000 | -36,774,000 | 217,873,000 | 66,517,000 | 196,675,000 |
| Dec 2025 | 41,227,000 | 31,112,000 | -12,097,000 | -14,155,000 | 256,846,000 | 57,217,000 | 201,255,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,724,000
Investing CF
$-13,078,000
Financing CF
$60,023,000
CapEx
$-1,820,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.57
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,261,597,000
Inventory
$9,498,000
Receivables
$144,173,000
ST Investments
$59,398,000
EBIT TTM
$-87,627,000
Pretax Income TTM
$-104,526,000
Interest Exp TTM
$16,899,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,804,992
EBITDA
$-64,452,000
Free Cash Flow
$99,187,000
Enterprise Value
$-112,218,320
Total Cash
$287,680,000
Total Debt
$34,862,000
Shares Out
63,908,946
Trailing EPS
$-2.30
Book Value
$0.39
ROE
-284.5%
ROA
-14.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 149,500,000 | -72,841,000 | -74,620,000 | 256,846,000 | 201,255,000 | 55,591,000 | -81,040,000 |
| Dec 2024 | 149,962,000 | -110,578,000 | -66,966,000 | 261,655,000 | 145,598,000 | 116,057,000 | -68,373,000 |
| Dec 2023 | 58,749,000 | -168,244,000 | -9,058,000 | 298,418,000 | 145,805,000 | 152,613,000 | -78,205,000 |
| Dec 2022 | 150,018,000 | -121,418,000 | -119,758,000 | 280,468,000 | 138,455,000 | 142,013,000 | -86,959,000 |
TTM Snapshot
Revenues TTM
$167,674,000
NetIncome TTM
$-14,592,000
OpCashFlow TTM
—
Assets (Latest)
$345,409,000
Forward EPS
$-1.54
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $1.97 · call volume: 1 · put volume: 60Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $131.54M | $6.20 | — |
| MENS | Jyong Biotech Ltd. | $133.62M | $1.80 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $124.92M | $4.33 | — |
| SION | Sionna Therapeutics, Inc. | $138.87M | $3.07 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $138.97M | $1.00 | — |
News headlines (Yahoo Finance, 1h cache)
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:25 · Yahoo
MacroGenics: Q3 Earnings Snapshot
2026-11-12 21:16 · Yahoo
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
2026-11-12 21:01 · Yahoo
MacroGenics to Participate in Upcoming Investor Conferences
2026-11-05 21:05 · Yahoo
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
2026-11-03 21:05 · Yahoo
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
2026-10-26 11:06 · Yahoo
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
2026-10-23 13:15 · Yahoo
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
2026-10-15 20:05 · Yahoo
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
2026-10-09 12:40 · Yahoo
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.